News

The acquisition includes parts of the site featuring various new manufacturing units for sterile injectables that are not currently operational. Hikma will retain the remaining plants including the

Indivior received a complete response letter from the FDA focusing on clinical pharmacology that found the early stage uptake of naloxone nasal spray did not fully meet the

The commission approved a variation of the drug to expand the existing therapeutic indication for Volibris, which can now be used as part of a combination treatment for

Entresto was studied in a clinical trial of over 8,000 patients with HFrEF and was shown to reduce the rate of cardiovascular death and hospitalizations related to heart

The study is being conducted in Vienna, Austria, and will examine the safety, tolerability, and pharmacokinetics of ASN100 in healthy volunteers. Arsanis chief development officer Rene Russo said:

Bristol-Myers Squibb has invested an undisclosed amount in LSP 5, the latest LSP fund. It is the first investment by the company in a European healthcare fund. A

There were no serious adverse events (SAE) observed in either of the treatment groups, and the incidence of adverse events (AE) was similar between treatment and control groups.

There are an estimated 300,000 total hip replacement surgeries performed in the U.S. each year. Without preventive anticoagulant treatment, the incidence of DVT ranges from 40 to 60

Genvoya is indicated in the European Union to treat adults and adolescents, aged 12 and older with body weight about 35 kg, infected with HIV-1 without any known